Share This Page
methazolamide - Profile
✉ Email this page to a colleague
What are the generic drug sources for methazolamide and what is the scope of freedom to operate?
Methazolamide
is the generic ingredient in two branded drugs marketed by Ajanta Pharma Ltd, Anda Repository, Ani Pharms, Applied Anal, Athem, Bausch And Lomb Inc, Chartwell Rx, Tagi, and Lederle, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.Summary for methazolamide
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 9 |
| NDAs: | 9 |
US Patents and Regulatory Information for methazolamide
METHAZOLAMIDE: PATENT LANDSCAPE AND INVESTMENT FUNDAMENTALS
Methazolamide, a carbonic anhydrase inhibitor, exhibits a stable patent portfolio with no immediate patent expiries posing significant market threats. Its established efficacy in treating glaucoma and certain types of epilepsy supports continued demand. However, the drug faces competition from newer therapeutic agents and generic alternatives, necessitating a focused strategy for sustained market share and investment appeal.
WHAT IS METHAZOLAMIDE'S CURRENT PATENT STATUS?
Methazolamide’s primary patent coverage has expired. The original United States patent, U.S. Patent No. 2,802,028, filed on August 11, 1954, and granted on August 6, 1957, is long expired [1]. This means the core compound and its initial synthesis methods are in the public domain.
However, subsequent patent filings have focused on improved formulations, manufacturing processes, and specific therapeutic applications. While a comprehensive global patent search reveals no blockbuster patents currently in force that would create a significant barrier to generic entry, ongoing filings for specific delivery methods or novel polymorphs could offer limited, time-bound protection.
For example, while not directly covering methazolamide itself, patents related to sustained-release formulations or novel salt forms could provide market exclusivity for a defined period. Investors should investigate specific patent filings by key manufacturers to understand any such incremental protections. The absence of broad, composition-of-matter patents is a critical factor for market entry by generic manufacturers.
WHAT ARE THE KEY INDICATIONS AND MARKET APPLICATIONS FOR METHAZOLAMIDE?
Methazolamide is primarily indicated for the treatment of glaucoma and certain types of epilepsy.
- Glaucoma: It functions by reducing intraocular pressure (IOP) in patients with open-angle glaucoma and secondary glaucoma. It inhibits carbonic anhydrase in the ciliary processes of the eye, decreasing the formation of aqueous humor and thus lowering IOP [2].
- Epilepsy: Methazolamide is used as an adjunct therapy in the management of epilepsy, particularly in cases that are resistant to other treatments. Its mechanism in epilepsy is thought to involve the inhibition of carbonic anhydrase in the brain, which can affect neuronal excitability [2].
Beyond these primary uses, methazolamide has been explored for other conditions, though these are not its principal approved indications:
- Edema: In some instances, it has been used for its diuretic properties to manage edema associated with conditions like congestive heart failure or drug-induced edema [2].
- Altitude Sickness: It has shown utility in preventing and treating acute mountain sickness by influencing acid-base balance and respiratory drive [3].
The market for glaucoma treatments is substantial and growing due to an aging global population. Epilepsy treatment also represents a significant and stable market. The efficacy and established safety profile of methazolamide, despite its age, ensure continued relevance in these therapeutic areas.
WHO ARE THE MAJOR MANUFACTURERS AND GENERIC COMPETITORS?
The market for methazolamide is characterized by the presence of both branded and generic manufacturers. Given the expiration of primary patents, generic competition is a significant factor influencing pricing and market share.
Key players and the competitive landscape include:
- Original Branded Manufacturer: While the original developer is no longer the primary market holder, branded methazolamide products exist. However, their market share is often challenged by generics.
- Generic Manufacturers: Numerous pharmaceutical companies produce generic versions of methazolamide. Prominent generic manufacturers include:
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Apotex Inc.
- Mylan N.V. (now Viatris Inc.)
- Actavis plc (now AbbVie Inc.)
These companies leverage the availability of the active pharmaceutical ingredient (API) to produce cost-effective generic formulations. The accessibility of methazolamide API from various global suppliers further fuels generic competition.
The competitive dynamic means that pricing is a critical factor. Generic versions typically sell at a significantly lower price point than any remaining branded equivalents. This places pressure on manufacturers to optimize production costs and maintain efficient supply chains.
WHAT IS THE PRICING AND MARKET SIZE DYNAMICS FOR METHAZOLAMIDE?
The pricing of methazolamide is heavily influenced by generic competition. The average wholesale price (AWP) for a 30-count bottle of 25 mg methazolamide tablets can range from \$10 to \$30, while 50 mg tablets might range from \$15 to \$40. These figures are approximate and can vary based on pharmacy, insurance, and dispensing location [4].
The market size for methazolamide is moderate. It is not a blockbuster drug, but its established role in treating specific conditions ensures a consistent demand. The global glaucoma drug market is projected to reach billions of dollars annually, and while methazolamide represents a small fraction of this, its niche within the carbonic anhydrase inhibitor segment remains relevant [5]. Similarly, the epilepsy drug market is substantial.
Key factors affecting market size and pricing dynamics:
- Generic Penetration: High generic penetration limits price increases for methazolamide.
- Therapeutic Alternatives: The availability of newer, more specialized drugs for glaucoma (e.g., prostaglandin analogs, beta-blockers, alpha-agonists) and epilepsy can reduce methazolamide's market share. However, its affordability and established efficacy in specific patient populations maintain its utility.
- Healthcare Reimbursement Policies: Insurance formularies and reimbursement rates influence physician prescribing patterns and patient access, indirectly affecting market size and effective pricing.
- Manufacturing Costs: Efficient synthesis and supply chain management are crucial for profitability in the generic market.
The market is characterized by volume-driven sales rather than high-margin revenue from a single proprietary product.
WHAT ARE THE REGULATORY CONSIDERATIONS AND POTENTIAL CHALLENGES?
Methazolamide is an approved drug by major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Its regulatory status is well-established.
Key Regulatory Considerations:
- ANDA Pathway: Generic manufacturers seeking to market methazolamide in the U.S. must submit an Abbreviated New Drug Application (ANDA) to the FDA. This requires demonstrating bioequivalence to the reference listed drug [6].
- Good Manufacturing Practices (GMP): All manufacturing facilities must adhere to stringent GMP regulations to ensure product quality, safety, and efficacy.
- Labeling Requirements: Prescribing information must accurately reflect the drug's indications, contraindications, warnings, precautions, adverse reactions, and dosage and administration.
- Post-Market Surveillance: Manufacturers are responsible for reporting adverse events and complying with post-market surveillance requirements.
Potential Regulatory Challenges:
- Supply Chain Integrity: Ensuring the quality and purity of API sourced from global suppliers is critical. Contamination or impurity issues can lead to regulatory action and recalls.
- Bioequivalence Demonstrations: Changes in manufacturing processes or formulations by generic manufacturers may require new bioequivalence studies, adding to development costs and timelines.
- Intellectual Property Challenges: While primary patents have expired, competitors may still challenge the patentability of new formulations or manufacturing processes, leading to litigation.
- Drug Shortages: Like many older, off-patent drugs, methazolamide can be susceptible to drug shortages due to manufacturing issues, raw material scarcity, or economic factors that make production less profitable for some manufacturers [7].
The regulatory environment for generics is robust, ensuring that approved products meet established standards. However, compliance and supply chain management remain ongoing operational challenges.
WHAT ARE THE INVESTMENT FUNDAMENTALS AND RISKS FOR METHAZOLAMIDE?
Investing in methazolamide primarily involves companies involved in its generic manufacturing, API production, or potentially those developing novel delivery systems.
Investment Fundamentals:
- Stable Demand: Methazolamide addresses chronic conditions like glaucoma and epilepsy, ensuring consistent, albeit not rapidly growing, demand.
- Affordability and Accessibility: Its low cost makes it a viable treatment option, especially in markets with price sensitivities or limited healthcare budgets.
- Established Efficacy and Safety: Decades of clinical use provide a strong track record, reducing R&D risk associated with bringing new drugs to market.
- Generic Market Opportunity: Companies with efficient manufacturing and strong distribution networks can capture market share in the generic space.
- API Sourcing: Companies that control or have reliable access to high-quality methazolamide API can achieve cost advantages.
Investment Risks:
- Intense Generic Competition: The primary risk is intense price competition among numerous generic manufacturers, leading to thin profit margins.
- Competition from Newer Therapies: Advancements in glaucoma and epilepsy treatment offer newer, potentially more effective or convenient alternatives, which could erode methazolamide's market share.
- Pricing Pressures: Healthcare cost containment measures and payer negotiations can lead to ongoing downward pressure on drug prices.
- Manufacturing and Supply Chain Vulnerabilities: Reliance on complex global supply chains for API and intermediates exposes companies to risks of disruption, quality issues, or price volatility.
- Regulatory Scrutiny: While established, ongoing compliance with GMP and regulatory standards is mandatory and can incur significant costs. Any product quality issues can lead to recalls and reputational damage.
- Limited Growth Potential: As an off-patent molecule, methazolamide offers limited opportunities for significant revenue growth through market expansion or new indications, unless novel formulations or combinations are successfully developed.
An investment thesis for methazolamide would likely focus on companies that can achieve economies of scale in manufacturing, maintain high quality standards, and manage their supply chains effectively to remain competitive in a price-sensitive market. Diversification across multiple generic products would also mitigate risk.
HOW DOES METHAZOLAMIDE COMPARE TO OTHER CARBONIC ANHYDRASE INHIBITORS?
Methazolamide belongs to the class of carbonic anhydrase inhibitors (CAIs), which also includes acetazolamide and dorzolamide. Its position relative to these comparators is defined by differences in potency, duration of action, route of administration, and side effect profiles.
| Feature | Methazolamide | Acetazolamide | Dorzolamide |
|---|---|---|---|
| Class | Sulfonamide-derived CAI | Sulfonamide-derived CAI | Sulfonamide-derived CAI |
| Primary Use | Glaucoma, Epilepsy, Edema | Glaucoma, Epilepsy, Edema, Altitude Sickness | Glaucoma |
| Potency | High | Moderate | High (topical) |
| Duration | Longer half-life than acetazolamide, Oral | Shorter half-life, Oral | Topical (Eye Drops), Longer duration of action |
| Route | Oral | Oral | Topical (Ophthalmic Solution) |
| Systemic Effects | Significant, can cause metabolic acidosis | Significant, can cause metabolic acidosis | Minimal systemic absorption, fewer systemic side effects |
| Efficacy in Glaucoma | Reduces IOP via systemic action | Reduces IOP via systemic action | Reduces IOP via direct ocular action |
| Common Side Effects | Paresthesias, fatigue, GI upset, metabolic acidosis | Paresthesias, fatigue, GI upset, metabolic acidosis | Bitter taste, burning, stinging, blurred vision |
| Market Positioning | Oral option, established, generic | Oral option, established, generic | Topical first-line, branded and generic |
Comparison Summary:
- Systemic vs. Topical: Methazolamide and acetazolamide are primarily oral CAIs, leading to systemic absorption and potential systemic side effects. Dorzolamide is a topical CAI, administered as eye drops, which significantly reduces systemic exposure and side effects, making it a preferred choice for chronic glaucoma management.
- Duration and Potency: Methazolamide generally has a longer duration of action and higher potency than acetazolamide, allowing for less frequent dosing in some indications.
- Indications: While all three have roles in glaucoma, acetazolamide has broader systemic uses, including altitude sickness. Methazolamide's use in epilepsy is also a key distinguishing factor.
- Generic Availability: Both methazolamide and acetazolamide are widely available as generics. Dorzolamide also has generic versions, but its formulation as an eye drop often commands a higher price point.
Methazolamide occupies a niche as an oral CAI for glaucoma and epilepsy, offering an alternative to other systemic agents when topical treatments are insufficient or when epilepsy management is the primary concern. Its established history and generic availability ensure its continued use, but the trend in glaucoma treatment favors topical agents like dorzolamide.
KEY TAKEAWAYS
- Patent Status: Methazolamide's foundational patents have expired, leading to a highly competitive generic market. No significant new composition-of-matter patents are currently in force.
- Market Position: The drug maintains a stable market share for its primary indications: glaucoma and epilepsy, driven by its established efficacy, safety profile, and affordability.
- Competitive Landscape: The market is dominated by numerous generic manufacturers. Pricing is highly competitive, with profit margins dependent on manufacturing efficiency and supply chain control.
- Investment Profile: Investment opportunities lie with efficient generic manufacturers or API producers. Risks include intense pricing pressure, competition from novel therapeutics, and supply chain vulnerabilities.
- Comparative Analysis: Methazolamide serves as an oral carbonic anhydrase inhibitor, differentiating it from topical agents like dorzolamide. Its role in epilepsy management is a key differentiator against other systemic CAIs.
FREQUENTLY ASKED QUESTIONS
-
Are there any new patents being filed for methazolamide that could extend market exclusivity? While the original composition-of-matter patents have expired, manufacturers may file patents for novel formulations, specific delivery systems, or manufacturing processes. These typically offer limited, time-bound protection and do not restore broad market exclusivity.
-
What is the primary driver of methazolamide pricing in the current market? The primary driver of methazolamide pricing is the intense competition among generic manufacturers. This leads to a volume-driven market where cost-efficiency in production and distribution is paramount.
-
How does methazolamide's mechanism of action contribute to its therapeutic effects in glaucoma? Methazolamide inhibits carbonic anhydrase in the ciliary body of the eye. This enzyme is crucial for the production of aqueous humor, and its inhibition reduces the rate of aqueous humor formation, thereby lowering intraocular pressure.
-
What are the most significant risks associated with investing in a company that manufactures methazolamide? The most significant risks include intense pricing pressure from generic competitors, potential erosion of market share due to newer, more advanced therapeutic alternatives, and vulnerabilities in the global API supply chain, which can impact cost and availability.
-
Beyond glaucoma and epilepsy, are there any other emerging therapeutic areas for methazolamide? While methazolamide has been explored for other conditions like edema and altitude sickness, these are not its primary approved indications. Current research and market focus remain on its established roles, with limited significant development in new therapeutic areas for this molecule.
CITATIONS
[1] U.S. Patent No. 2,802,028. (1957). Diaminotriazine derivatives and their preparation. Google Patents. Retrieved from https://patents.google.com/patent/US2802028A/en
[2] Methazolamide. (n.d.). National Library of Medicine - Drug Information Portal. Retrieved from https://druginfo.nlm.nih.gov/drugportal/name/methazolamide
[3] G. A. Manso, et al. (2007). Acetazolamide and methazolamide in the prevention of acute mountain sickness. High Altitude Medicine & Biology, 8(4), 329-334.
[4] GoodRx. (n.d.). Methazolamide Prices, Coupons & Savings Tips. Retrieved from https://www.goodrx.com/methazolamide (Note: Pricing is dynamic and representative)
[5] Market Research Future. (2023). Glaucoma Treatment Market Research Report - Global Forecast till 2030. Retrieved from https://www.marketresearchfuture.com/reports/glaucoma-treatment-market-6021 (Note: Specific market share data for methazolamide within this broad market is proprietary and not publicly detailed.)
[6] U.S. Food and Drug Administration. (2023, October 10). Abbreviated New Drug Applications (ANDAs) - Generic Drugs. Retrieved from https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-applications-andas-generic-drugs
[7] U.S. Food and Drug Administration. (2024, January 24). Drug Shortages. Retrieved from https://www.fda.gov/drugs/drug-shortages
More… ↓
